Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
results will be fascinating. big funding with giant pharma.will go to the moon.
watch out shorties it aint for you now.
heard it through the grapevine.if u know wht i mean.
they will make that fact public soon!
im sure they have data from lab rats.
News: $MBRX Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
HOUSTON , July 21, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that a second round of inde...
Read the whole news MBRX - Moleculin Announces New Independent In Vitro Testing Confirms Antiviral Activity of WP1122 in Coronavirus
This pos never holds up what a waste ? Imo
Yes I’m gonna take some myself today !
$2.50 gap mhop $$$$
It’s a great opportunity to exit at a profit. They seem to keep repeating in vitro tests but no info on what’s next or any timeline for trials. Notably they’ve stopped providing any updates on anything other than Covid-19 testing.
And we are off to the races this morning $$$$$
Understanding this is the key to understanding why WP1122 may represent a major breakthrough. Glycolysis and glycosylation sound similar, but they are very different, even though they rely on the same base material, glucose, which is essentially sugar. In highly simplified terms, glycolysis converts glucose into fuel and glycosylation uses glucose to help build important protein structures that enable the way our cells function with each other and respond to changes in their environment. When viruses like SARS-CoV-2 invade our cells, they coopt these processes to increase both their infectivity and their replication.
The Slightly Longer Version
Moleculin has a unique opportunity to contribute to the global challenge posed by coronavirus and other viruses threatening our communities. We recently announced a collaboration with a major Texas university institution to evaluate our drug candidate, WP1122, and its analogs and this has now been followed by collaborations with additional players who bring the needed expertise to fully develop this new potential treatment for diseases like COVID-19.
Independent researchers at the Institute of Biochemistry II – Goethe-Universität Frankfurt in Germany recently announced their discovery that 2-DG, the active compound in WP1122, reduced in vitro replication of SARS-CoV-2 by 100%.
We now have a very strong reason to believe that WP1122 may be effective against COVID-19. This is based on the vital roles that glucose plays in the proliferation of SARS-CoV-2. Viruses like SARS-CoV-2 place increased demand on glucose and upregulate their host cell’s metabolic processes. Some of the most important of these processes are believed to be glycolysis and glycosylation.
Tackling Coronavirus with WP1122
The Short Version
Viruses (like SARS-CoV-2) depend on glycolysis and glycosylation for infectivity and replication.
Glycolysis and glycosylation can be disrupted by using a glucose decoy known as 2-DG.
And, while 2-DG has been shown to be effective in vitro, 2-DG’s lack of drug-like properties makes it ineffective as a drug in humans.
WP1122 has the potential to solve 2-DG’s problem by creating a prodrug of 2-DG that reaches much higher tissue/organ concentrations than 2-DG alone.
We are moving as quickly as possible to prepare WP1122 for clinical evaluation in the treatment of COVID-19.
Straight from the horses mouth.
Tackling COVID-19 with WP1122
We have a unique opportunity to contribute to the global challenge posed by coronavirus and other viruses threatening our communities. The active compound in WP1122 was found to reduce in vitro replication of SARS-CoV-2 by 100%.
How is everyone feeling about MBRX? From what I know, the company is doing very well with progress, development and seeking approval.
I have a feeling something good or should I say very good is brewing and this is what we are reading all the recent news and moves the company is doing.
I believe the WP1122 is going to kick butt and is going to stop covid in its track 100%. The key is to stop the replication and so far the science in the lab proved that, I am sure since then a lot of progress has bee taking place behind the scene.
Let's keep each other posted and updated. its a win for all.
Negative energy has no place in my book, so to all the negative people, don't waste your time replying garbage.
Yup, they hit the ATM I also saw that one coming and sold on the hype day expecting the stock sale.
Went to minimum number of shares averaged at .90.
They just announced manufacturing more WP1122 for further testing before they submit the IND. Maybe that will happen in August. No substantial news till then. This should drop again.
I expect another press release tomorrow announcing yet another dilutive financing where the broker will dump shares before sending the company money ??
Closed at $1.07 and expect to see it below $1 again. Good luck..
* * $MBRX Video Chart 07-15-2020 * *
Link to Video - click here to watch the technical chart video
News: $MBRX Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
HOUSTON , July 15, 2020 /PRNewswire/ -- Moleculin Biotech, Inc., (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, today announced that it has entered into an...
Got this from MBRX - Moleculin Announces Agreement to Produce WP1122 for Expanded Development of Potential COVID-19 and Oncology Drug Candidate
$1.28 now. The news is good.
1.10 in Pre Mkt on news but I doubt it will hold.
They received a compliance notice after that, they will likely get another deficiency notice again, and be given 6 months to regain compliance...
Not anymore. The countdown has started. They will either get booted off the exchange or implement the reverse split to try to prevent that from happening. Either way current shareholders are screwed.
It’s really sad what they’ve done to this company. Not to mention how they’ve squandered a chance to help people with serious illness. Shareholders will likely lose any remaining value within a year.
What does that have to do with Moleculin today ?
They have been over a dollar for much more than 10 business days.
The clock has been reset, and within 30 days they will be much closer to an IND and if they are allowed to use existing data they may be on their way to in vivo trials.
Thanks..Let's hope for something more positive... But given the history.. probably something to plan on.
11. Moleculin received a deficiency letter from NASDAQ on March 20, 2020
because its bid price for the company’s common stock closed under $1.00 over the preceding
thirty consecutive business days in violation of NASDAQ Listing Rule 5550(a)(2). The
company reported in a Form 8-K filed with the Commission on April 23, 2020 that it had
regained compliance with the rule because the bid price closed above $1.00 for ten consecutive
business days during the period from April 8 through April 22, 2020. Moleculin’s ability to
regain compliance with NASDAQ listing requirements coincides with its statements regarding a
potential treatment for COVID-19
https://www.sec.gov/litigation/apdocuments/3-19801-event-2020-05-21-information-before-the-commisson-at-the-time-of-trading-suspension.pdf
Proposal 3. To Effect a Reverse Stock Split of the Outstanding Shares - - The Company’s stockholders authorized the Board of Directors, in its sole discretion, prior to the one-year anniversary of the Annual Meeting, to file an amendment to the Company’s Amended and Restated Certificate of Incorporation to effect a reverse stock split at one of the following reverse stock split ratios, 1-for-2, 1-for-3, 1-for-4, 1-for-5, 1-for-6, 1-for-7, or 1-for-8. As of the date hereof, the Company's Board of Directors has not made any determination on the filing of such amendment. The voting on this proposal is set forth below:...
https://ih.advfn.com/stock-market/NASDAQ/moleculin-biotech-MBRX/stock-news/82681437/current-report-filing-8-k
They're sweating the listing standard instead of focusing on moving forward. No one likes reverse splits. Move the science and bring in more peer review.
Just saying there's plenty they could do besides keeping money on the sidelines watching and waiting.
It looks like many have given up. It’s too bad. The company had a promising treatment but seems to have forgotten about the original purpose.
Sold over 40k shares today. May buy back in after the split.
Agree. I like the potential, that's why I'm still here.
I hate splits.
they really have no choice if they want to maintain their nasdaq listing.
I bailed a while back. 1 I hate splits.
2 I hate splits.
What I do like though is the volatility after the split.
Still keeping this on my radar though.
Made my green 1st though!!
another bloodbath. it will break the $1 level soon and then look out below.
no, shareholders did not vote to increase salaries and award more stock options.
They? Was this not voted on by shareholders?
As expected, they approved to reverse split the stock and increase number of shares outstanding. Very bad for current shareholders, but great for management and directors, who by the way awarded themselves massive increase in salary and stock options. Great job!
Followers
|
90
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
3504
|
Created
|
06/17/16
|
Type
|
Free
|
Moderators |
WALTER V. KLEMP
President, CEO and Chairman
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |